Auditory EEG Biomarkers in Fragile X Syndrome: Clinical Relevance by Ethridge, Lauren E. et al.
fnint-13-00060 October 5, 2019 Time: 14:39 # 1
ORIGINAL RESEARCH








Boston Children’s Hospital, Harvard







Received: 16 March 2019
Accepted: 24 September 2019
Published: 09 October 2019
Citation:
Ethridge LE, De Stefano LA,
Schmitt LM, Woodruff NE, Brown KL,
Tran M, Wang J, Pedapati EV,
Erickson CA and Sweeney JA (2019)
Auditory EEG Biomarkers in Fragile X
Syndrome: Clinical Relevance.
Front. Integr. Neurosci. 13:60.
doi: 10.3389/fnint.2019.00060
Auditory EEG Biomarkers in Fragile X
Syndrome: Clinical Relevance
Lauren E. Ethridge1,2* , Lisa A. De Stefano2, Lauren M. Schmitt3,4, Nicholas E. Woodruff2,
Kara L. Brown2, Morgan Tran2, Jun Wang5, Ernest V. Pedapati4,6,7, Craig A. Erickson4,6
and John A. Sweeney4
1 Department of Pediatrics, Section of Developmental and Behavioral Pediatrics, The University of Oklahoma Health
Sciences Center, Oklahoma City, OK, United States, 2 Department of Psychology, The University of Oklahoma, Norman, OK,
United States, 3 Division of Developmental and Behavioral Pediatrics, Cincinnati Children’s Hospital Medical Center,
Cincinnati, OH, United States, 4 Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati,
OH, United States, 5 Department of Psychology, Zhejiang Normal University, Jinhua, China, 6 Division of Child
and Adolescent Psychiatry, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States, 7 Division of Child
Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States
Sensory hypersensitivities are common and distressing features of Fragile X Syndrome
(FXS). While there are many drug interventions that reduce behavioral deficits in Fmr1
mice and efforts to translate these preclinical breakthroughs into clinical trials for FXS,
evidence-based clinical interventions are almost non-existent potentially due to lack
of valid neural biomarkers. Local circuit function in sensory networks is dependent
on the dynamic balance of activity in inhibitory/excitatory synapses. Studies are
needed to examine the association of electrophysiological alterations in neural systems
with sensory and other clinical features of FXS to establish their clinical relevance.
Adolescents and adults with FXS (n = 38, Mean age = 25.5, std = 10.1; 13 females)
and age matched typically developing controls (n = 40, Mean age = 27.7, std = 12.1;
17 females) completed auditory chirp and auditory habituation tasks while undergoing
dense array electroencephalography (EEG). Amplitude, latency, and percent change
(habituation) in N1 and P2 event-related potential (ERP) components were characterized
for the habituation task; time-frequency calculations using Morlet wavelets characterized
phase-locking and single trial power for the habituation and chirp tasks. FXS patients
showed increased amplitude but some evidence for reduced habituation of the N1 ERP,
and reduced phase-locking in the low and high gamma frequency range and increased
low gamma power to the chirp stimulus. FXS showed increased theta power in both
tasks. While the habituation finding was weaker than previously found, the remaining
findings replicate our previous work in a new sample of patients with FXS. Females
showed less deficit in the chirp task but not the habituation task. Abnormal increases
in gamma power were related to more severe behavioral and psychiatric features as
well as reductions in neurocognitive abilities. Replicating electrophysiological deficits
in a new group of patients using different EEG equipment at a new data collection
site with differing levels of environmental noise that were robust to data processing
techniques utilizing multiple researchers, indicates a potential for scalability to multi-site
clinical trials. Given the robust replicability, relevance to clinical measures, and preclinical
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evidence for sensitivity of these EEG measures to pharmacological intervention, the
observed abnormalities may provide novel translational markers of target engagement
and potentially outcome measures in large-scale studies evaluating new treatments
targeting neural hyperexcitability in FXS.
Keywords: Fragile X Syndrome, EEG, chirp, habituation, gamma, sensory
INTRODUCTION
While there are many drug interventions that reduce behavioral
deficits in Fmr1 mice and efforts to translate these preclinical
breakthroughs into clinical trials for Fragile X Syndrome (FXS)
(Tranfaglia, 2011; Wijetunge et al., 2013; Budimirovic et al., 2017;
Berry-Kravis et al., 2018; Erickson et al., 2018), evidence-based
clinical interventions are almost non-existent (Berry-Kravis et al.,
2018). One advance that may speed progress in treatment
development is the establishment of valid biomarkers of brain
activity that can be used to stratify patients based on presence of
abnormalities targeted by novel drugs (Erickson et al., 2018).
Auditory hypersensitivities and other sensory processing
abnormalities are common in FXS as well as idiopathic autism
spectrum disorder (ASD) (Takarae et al., 2007, 2014; Hagerman,
2008; Hall et al., 2009; Matsuzaki et al., 2012; Ethridge et al., 2017).
Our previous electroencephalography (EEG) and event-related
potential (ERP) studies demonstrated electrophysiological
phenotypes that show considerable conservation across Fmr1
knock-out (KO) mice and FXS patients, indicating that they may
represent promising biomarkers for FXS. However, replication
in a larger independent patient population, evaluation of clinical
correlates, addressing specificity, and evaluation of scalability
considerations in data collection are needed to further validate
these evoked EEG measures.
Our previous findings showed significantly increased non-
specific gamma activity (gamma single-trial power) in FXS
that was associated with a decreased ability to (1) transiently
synchronize evoked gamma (the “gamma spike” during early
stimulus registration), (2) to synchronize evoked gamma to a
rapidly changing oscillatory “chirp” stimulus (Ethridge et al.,
2017) and (3) to habituate the neural response to repeated
tones (Ethridge et al., 2016). These abnormalities were associated
with increased clinical measures of sensory hypersensitivity,
suggesting altered gamma oscillations/neural hyper-excitability
are a potential biomarker of sensory issues in FXS. Still whether
this potential biomarker has clinical relevance beyond sensory
issues, including links to cardinal behavioral and cognitive
features, remains unknown.
Gamma band activity has established neural mechanisms,
which include the local circuit glutamate/GABA interactions
involving excitation onto and inhibition originating from
parvalbumin positive (PV+) fast-spiking interneurons (the
Abbreviations: Db, decibels; EEG, electroencephalography; ERP, event-related
potential; FXS, Fragile X Syndrome; GLU, glutamate; Hz, Hertz; ICA, independent
components analysis; IQ, intelligence quotient; ITC, inter-trial coherence;
KO, knockout; Ms, milliseconds; PCA, principal components analysis; PV+,
parvalbumin positive; SCQ, social communication questionnaire; SNR, signal-to-
noise ratio; STP, single trial power.
PING model), and mutually connected inhibitory interneurons
(the ING model) (Gibson et al., 2008; Cardin et al., 2009; Tiesinga
and Sejnowski, 2009). During sensory processing gamma is
associated with bottom-up sensory processing of basic stimulus
properties (Brosch et al., 2002). Reduced local circuit inhibition
via the PING model has been proposed as a neural mechanism
for sensory hypersensitivity and neural hyper-excitability in FXS
(Gibson et al., 2008; Paluszkiewicz et al., 2011). Importantly,
these neural phenotypes have been largely replicated in Fmr1
KO mice, including increased gamma power and abnormal
synchronization at both the in vivo (Sinclair et al., 2017;
Lovelace et al., 2018) and in vitro (Goswami et al., 2019) levels.
Gamma power and synchronization abnormalities also show
preclinical responsiveness to both genetic (Wen et al., 2018)
and pharmaceutical (Sinclair et al., 2017; Lovelace et al., 2018)
intervention. Together these convergent translational findings
suggest altered local inhibitory networks in FXS pathophysiology
can be evaluated using electrophysiology, and the findings may
be predictive of clinical/behavioral pathologies relevant to drug
development and testing.
The current study aimed to replicate previous EEG/ERP
results in a larger sample of FXS patients from a different data
collection site using different EEG equipment. The larger sample
also enabled evaluation of gender differences in these phenotypes.
In our previous preliminary study, clinical evaluation to
establish correlation with electrophysiology was modest. In the
current study, considerably more clinical data was collected to
better establish the relevance of traditional electrophysiological
measures with psychological and behavioral measures. We
hypothesized that gamma measures would largely replicate in
the new sample, be associated with both sensory and behavioral
clinical measures, and be robust to reasonable levels of variability
introduced by larger-scale data collection and analysis efforts.
We further predicted that females with FXS would show reduced
EEG/ERP abnormalities relative to males with FXS, consistent




Thirty-eight adolescents and adults with full mutation FXS
[Mean (M) age = 25.5, standard deviation (SD) = 10.1;
age range 10–53; 13 females] and 40 age- and sex-matched
typically developing controls (M age = 27.7, SD = 12.1; age
range 12–57; 17 females) participated in the study (Table 1).
Most participants completed both habituation and chirp EEG
tasks, but see Table 1 for exact demographic breakdown per
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TABLE 1 | Participant characteristics.
FXS n = 38 (13 females) Controls n = 40 (17 females)
Mean Std. Dev. Range Mean Std. Dev. Range t Statistic (df)
Total sample
Age 25.5 10.1 10 to 53 Age 27.7 12.1 12 to 57 t(76) = 0.9, p = 0.37
Full scale IQ 60.3 20.9 47 to 115 Full Scale IQ 103.8 10.4 85 to 124 t(73) = 11.5, p < 0.001
Verbal Z −3.0 1.9 −6.5 to 0.2 Verbal Z 0.14 0.71 −1.4 to 2 t(71) = 9.4, p < 0.001
Non-verbal Z −4.6 2.4 −8.6 to −0.4 Non-verbal Z 0.21 0.76 −1.1 to 1.8 t(71) = 11.2, p < 0.001
Deviation IQ 41.7 28.9 −10.8 to 94.1 Deviation IQ 102.7 8.4 88.9 to 120.8 t(71) = 11.9, p < 0.001
SCQ 14.0 7.9 1 to 29 SCQ 2.2 2.4 0 to 8 t(63) = 8.0, p < 0.001
FXS n = 30 (12 females) Controls n = 37 (16 females)
Mean Std. Dev. Range Mean Std. Dev. Range t Statistic (df)
Participants completing habituation task
Age 25.7 10.5 13 to 53 Age 26.8 11.9 12 to 45 t(65) = 0.4, p = 0.69
Full scale IQ 62.4 21.6 47 to 115 Full scale IQ 103.1 9.9 85 to 124 t(62) = 10.1, p < 0.001
Verbal Z −2.8 1.8 −6.5 to −0.3 Verbal Z 0.1 0.6 −1.4 to 1.5 t(60) = 8.9, p < 0.001
Non-verbal Z −4.6 2.6 −8.6 to −0.4 Non-verbal Z 0.2 0.8 −1.1 to 1.8 t(60) = 10.3, p < 0.001
Deviation IQ 43.7 30.2 −10.8 to 94.1 Deviation IQ 102.1 8.1 88.9 to 120.8 t(60) = 11.1, p < 0.001
SCQ 13.8 8.1 1 to 29 SCQ 2.3 2.4 0 to 8 t(54) = 7.7, p < 0.001
FXS n = 36 (13 females) Controls n = 39 (17 females)
Mean Std. Dev. Range Mean Std. Dev. Range t Statistic (df)
Participants completing chirp task
Age 25.4 10.2 10 to 53 Age 27.9 12.2 12 to 57 t(73) = 0.9, p = 0.33
Full scale IQ 60.7 20.4 47 to 115 Full scale IQ 104.2 10.2 85 to 124 t(71) = 11.8, p < 0.001
Verbal Z −3.0 1.9 −6.5 to 0.2 Verbal Z 0.2 0.7 −1.4 to 2.0 t(69) = 9.6, p < 0.001
Non-verbal Z −4.5 2.4 −8.6 to −0.4 Non-verbal Z 0.2 0.7 −1.1 to 1.8 t(69) = 11.6, p < 0.001
Deviation IQ 42.4 29.1 −10.8 to 94.1 Deviation IQ 102.9 8.3 88.9 to 120.8 t(69) = 12.3, p < 0.001
SCQ 14.0 7.9 1 to 29 SCQ 2.2 2.4 0 to 8 t(62) = 8.2, p < 0.001
SCQ, social and communication questionnaire.
task. Groups did not differ on proportion of each sex either
overall (chi square = 0.57, p = 0.45), for the habituation
task (chi square = 0.07, p = 0.79) or for the chirp task (chi
square = 0.44, p = 0.51). Typically developing controls (TDC)
had no known prior diagnosis or treatment for neuropsychiatric
illness (reported via clinical history interview with parent or
participant as appropriate). Exclusion criteria included history of
seizures and current use of medications with known EEG effects,
including anticonvulsant medications and benzodiazepines. Five
patients were receiving atypical antipsychotics, 8 antidepressants,
8 both antipsychotics and antidepressants all on a stable dose
for at least 4 weeks (see Supplementary Table 1 for a complete
list). While medication effects cannot be ruled out, removing
patients based on presence of commonly prescribed psychiatric
medications would produce a sample that is non-representative
of the FXS population. Our previous work and other EEG
studies of these drugs in psychiatric research suggest they do
not have significant confounding effects on electrophysiology
as measured in the current study (Mitra et al., 2015; Ahnaou
et al., 2016; Clementz et al., 2016; Ethridge et al., 2016,
2017); we also did not find any significant differences between
medicated and non-medicated patients on any of the EEG
variables studied here.
Primary caregivers completed the following clinical
assessment measures for FXS patients: The Caregiver Report
Adolescent and Adult Sensory Profile (Brown et al., 2001),
the Social and Communication Questionnaire (SCQ; Rutter
et al., 2003), Anxiety Depression and Mood Scale (ADAMS,
Esbensen et al., 2003), Aberrant Behavior Checklist-Community
(ABC-C, optimized for FXS, Sansone et al., 2012). We also
administered the Woodcock-Johnson III Tests of Cognitive
Abilities Auditory Attention subscale (McGrew and Woodcock,
2001), the Vineland Adaptive Behavior Scales (Sparrow et al.,
2005) and the computerized Test of Attentional Performance
for Children (KiTAP, Knox et al., 2012). IQ was assessed for
both FXS and TDC with the Stanford-Binet Intelligence Scale
5th Ed. Abbreviated IQ (Roid, 2003) using deviation scores
for calculating verbal and non-verbal IQ in the lower IQ range
using the technique proposed by Sansone et al. (2014). Typically
developing controls completed the SCQ, ADAMS, ABC-C, and
KiTAP. All participants provided written informed consent
(caregiver with assent or individual consent as appropriate)
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prior to participation, as approved by the Cincinnati Children’s
Hospital Institutional Review Board.
Procedure
Habituation Task
The auditory habituation stimulus consisted of 150 stimulus
trains of four 50 ms duration white noise bursts separated
by 500 ms inter-stimulus intervals. Each stimulus train was
separated by a 4000 ms inter-trial interval. Habituation in this
task is characterized as the change in ERP amplitude for each
repetition in a stimulus train compared to the ERP amplitude
to the initial stimulus in a train (e.g., initial N1 to 2nd N1, 3rd
N1, and 4th N1).
Chirp Task
The auditory chirp stimulus consisted of a white noise burst
carrier stimulus amplitude modulated by a sinusoid linearly
increasing in frequency from 0 to 100 Hz over 2000 ms (16).
Chirp stimuli were presented 200 times each separated by an
inter-trial interval randomly jittered between 1500 and 2000 ms.
For both EEG tasks, stimuli were delivered at 65 db SPL through
headphones. Participants watched a silent movie during testing to
facilitate compliance with testing procedures as in prior studies
(Ethridge et al., 2016, 2017).
ERP Recording
EEG was continuously recorded and digitized at 1000 Hz,
filtered from 0.01 to 200 Hz, referenced to Cz, and amplified
10,000x using a 128 channel saline-based Electrical Geodesics
system (EGI, Eugene, Oregon) with sensors placed approximately
according to the International 10/10 system (42% of sensors in
128 channel EGI Hydrocel nets have 10–10 equivalents, while
an additional 42% are within a 2 cm tolerance; Chatrian, 1985;
Luu and Ferree, 2005).
EEG Analysis
Raw data were visually inspected offline. Bad sensors were
interpolated (no more than 5% per subject, no more than two
adjacent, 90% of participants had no sensors interpolated within
the 23 channels used in the final analyses) using spherical
spline interpolation implemented in BESA 6.1 (MEGIS Software,
Grafelfing, Germany). Data were digitally filtered from 0.5 to
120 Hz (12 and 24 db/octave roll-off, respectively; zero-phase;
60 Hz notch). Eye movement, cardiac, and muscle movement
artifacts were removed blind to participant group using
independent components analysis (ICA; Infomax) implemented
in EEGLAB (Delorme and Makeig, 2004) using Matlab (The
Mathworks, Natick, MA, United States). Segments of data with
large amounts of movement artifact were removed prior to ICA
to facilitate algorithm convergence. For both tasks, data were
then transformed to average reference and epoched into 3250 ms
trials (−500 to 2750 ms). For ERP analyses, data were averaged
across trials and baseline-corrected using the 500 ms pre-stimulus
period. Any trial with post-ICA amplitude exceeding 120 µV
was considered residual artifact and removed prior to averaging.
ERP averages for the habituation task were then low-pass filtered
at 40 Hz for ERP analyses, while chirp averages and single trial
power data for both tasks were retained at a low-pass filter of
120 Hz. Number of valid trials retained after artifact correction
was higher for controls compared to FXS for the habituation
task (FXS M = 105.5, SD = 22.4; Control M = 119.6, SD = 20.2,
t(66) = 2.7, p = 0.008) and the chirp task (FXS M = 128.7,
SD = 34.8; Control M = 152.9, SD = 32.7, t(75) = 3.2, p = 0.002),
therefore trial count was evaluated as a covariate for all analyses
and retained when significant.
Analyses in our previous studies used spatial principal
components analysis (PCA) on the grand average ERP in order to
create component weights using all sensors (Ethridge et al., 2016,
2017). However, the use of data-driven analyses is ultimately not
scalable to clinical trials, which require a priori thresholds and
defined regions of interest that can be calculated at the individual
level without waiting for availability of large group averages for
patient stratification. Therefore, we selected and averaged over
23 sensors distributed across the fronto-central scalp a priori
based on the spatial distribution most consistent with previous
literature capturing auditory cortex activity (Figure 1; Luck,
2014) and the peak of spatial activity from our previous PCA
results (Ethridge et al., 2016, 2017). All analyses were conducted
on data averaged over the same 23 sensors for both tasks.
For both tasks, un-baseline-corrected epoched single-trial
data were analyzed in the time-frequency domain using Morlet
wavelets with 1 Hz frequency step using a linearly increasing
cycle length from 1 cycle at the lowest frequency (2 Hz) to
30 cycles at the highest (120 Hz). Single-trial power (STP) and
inter-trial coherence (ITC) measures obtained from this method
evaluated the amplitude of response at each frequency and how
stable or phase-locked responses were to the auditory stimuli
across trials, respectively (Delorme and Makeig, 2004). Raw ITC
values were initially corrected for trial number by subtracting the
critical r value, calculated as sqrt[-1/(number of trials)∗log(0.5)],
for each subject based on trial count. STP and ITC values were
averaged over trials for each individual and transformed into
time-frequency plots down-sampled to 250 time-bins.
Single trial power was then baseline corrected using the
pre-stimulus period, up to 50 ms prior to stimulus onset, to
avoid windowing effects from stimulus onset-related activity.
Subsequent analyses followed the same method as those done
with non-baseline corrected single trial power.
Statistical Analysis
For habituation ERP analyses, the waveform components of
interest were the N1 and P2 components for the initial stimulus
and each repeated stimulus in the stimulus train. N1 and P2
peaks were defined as the minimum and maximum amplitudes,
respectively, in a time window centered on the grand average
peak amplitude ± 40 ms. Amplitude and latency were calculated
for each participant average at each peak. Separate mixed effects
ANOVAs were calculated for amplitude and latency of each peak
with the between subjects factors group (FXS, TDC) and gender
(M,F) and within subjects factor stimulus repetition (initial
stimulus, repetition 1, repetition 2, repetition 3). Differences
in habituation of the N1 and P2 waveforms were calculated
as the group by stimulus repetition interaction, indicating a
difference between groups in the change in amplitude or latency
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FIGURE 1 | Sensor layout for the EGI 128 channel system with selected sensors analyzed highlighted in red. Sensors were selected based on the traditional location
of the N1 ERP component, originating from auditory cortices, and from previous work.
across repetitions. Habituation was also calculated as percent
change in N1 amplitude across repetitions, to match with
our previous work.
For single-trial EEG analyses for both tasks, point-by-point
two-tailed t-tests were used to calculate group differences
across the time-frequency matrix. Time-frequency clustering
techniques and Monte Carlo simulations controlled for multiple
comparisons (Ethridge et al., 2012, 2017). To maintain a family-
wise alpha of p < 0.01 (corrected for multiple comparisons),
a minimum of three sequential time-bins and three adjacent
frequencies were required to be significant at a nominal threshold
of p < 0.05. Data were then averaged within each cluster
to produce a single value for clinical correlations as well as
univariate ANOVAs with fixed factors of group and gender. For
all analyses, trial number and age were evaluated as covariates
and retained in the model when significant. Effect sizes are
reported as partial eta squared. Means presented are estimated
marginal means.
Clinical correlations were examined with all significant
variables. We also examined exploratory correlations between
power in all frequency bands (theta, alpha, beta, gamma)
and hypothesis-driven associations between gamma STP and
gamma ITC. All correlations were conducted using Spearman’s
rho. Clinical correlations and power band correlations were
considered to be exploratory and hypothesis generating, and thus
not corrected for multiple comparisons.
RESULTS
Participant Demographics
There were no significant differences between FXS and TDC in
age or proportion of gender. As expected with this clinical sample,
FXS had significantly lower IQ scores and significantly higher
number of autism-like symptoms on the SCQ than TDC (see
Table 1 for detail).
EEG
Habituation
For N1 amplitude (Figure 2), there was a main effect of group,
F(1,62) = 11.833, p = 0.001, ES = 0.16 indicating that FXS
patients had larger N1 amplitudes (M = −1.47 µV, standard
error (SE) = 0.13) than TDC (M = −0.85 µV, SE = 0.12).
There was a marginal main effect of repetition F(3,186) = 2.5,
p = 0.05, ES = 0.04 with a significant linear contrast F(1,62) = 6.07,
p = 0.02, ES = 0.09. Pairwise comparisons to further examine this
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FIGURE 2 | ERP average waveforms for FXS and TDC for the habituation task. Black marks along the x-axis indicate stimulus timing for the four stimuli in each train.
Error bars indicate standard error of the mean. Note the increased N1 (negative peaks) and P2 (positive peaks) amplitude in FXS relative to TDC.
combination of effects indicated that N1 amplitude significantly
(p < 0.001 for all repetitions) decreased across repetitions relative
to the initial stimulus onset, but repetitions did not differ from
each other, describing the plateau effect of subsequent repetitions:
(N1 initial stimulus M = −1.60 µV, SE = 0.13; N1 repetition
1 M = −1.12 µV, SE = 0.10, N1 repetition 2 M = −0.99 µV,
SE = 0.09, N1 repetition 3 M = −0.91 µV, SE = 0.09). There
was no group by repetition effect, F(3,189) = 0.60, p = 0.61,
ES = 0.01 suggesting that while FXS had larger N1 amplitudes
overall, they did not habituate differently from TDC across
repetitions. A repetition by gender effect F(3,186) = 2.67,
p = 0.048, ES = 0.04 suggests that females plateau more
strongly than males, who continue to decrease N1 amplitude
across repetitions. Age was a significant covariate in the model
F(1,62) = 7.13, p = 0.01, ES = 0.10, consistent with the literature
that supports effects of age on N1 amplitude (Pang and Taylor,
2000), however age did not interact significantly with repetition
effects (p = 0.21). There was no significant effect of trial
count (p = 0.63). Similarly to our previous findings, we also
quantified N1 habituation as percent change from N1 for the
initial stimulus to each subsequent stimulus, however, FXS and
TDC also did not differ on this comparison, F(2,124) = 0.61,
p = 0.55, ES = 0.01 across all repetitions. Estimated marginal
means for this comparison did show a large difference at
the final repetition (percent reduction from initial stimulus
to the last repetition in the train: FXS M = 25%, SE = 8%;
TDC M = 51%, SE = 8%), suggesting that while it was not
a strong effect, FXS may have shown decreased habituation
relative to TDC by the end of the stimulus train. There were
no differences between groups for N1 latency. There were no
significant effects of age or trial count on percent change or N1
latency (p’s > 0.10).
Results were similar for P2 amplitude: there was a main
effect of group, F(1,63) = 7.5, p = 0.008, ES = 0.11 indicating
that FXS had larger P2 amplitudes (M = 1.37, SE = 0.10)
than TDC (M = 0.99, SE = 0.09). There was a main effect of
repetition, F(3,189) = 75.35, p < 0.001, ES = 0.55 indicating
habituation of the P2 amplitude across repetitions (P2 initial
stimulus M = 1.95, SE = 0.13; P2 repetition 1 M = 0.99,
SE = 0.07, P2 repetition 2 M = 0.94, SE = 0.06, P2 repetition
3 M = 0.85, SE = 0.07). Again there were no group by
repetition or gender effects, suggesting that although FXS patients
had larger P2 amplitudes, they did not habituate differently.
Age was not a significant covariate (p < 0.10). There was a
main effect of group for P2 latency F(1,62) = 5.2, p = 0.03,
ES = 0.08 such that FXS (M = 173.1 ms, SE = 2.47) had faster
latencies than TDC (M = 180.7 ms, SE = 2.2). Age was a
significant covariate F(1,62) = 4.09, p = 0.04, ES = 0.06. There
were no significant effects of trial count on P2 amplitude or
latency (p’s > 0.05).
Point-by-point t-tests on non-baseline-corrected time-
frequency plots for ITC and STP (corrected for multiple
comparisons) revealed 3 time-frequency clusters with significant
differences between FXS and TDC (Figure 3), all of which
were in single trial power. Power values differences were
largely consistent across the entire trial, including in the
baseline, so values for each cluster were averaged across the
entire trial and significant frequency range. For each of these
comparisons, trial number was a significant covariate and
retained in the analyses, but age was not a significant covariate.
For theta (3–7 Hz) power, there was a main effect of group,
F(1,62) = 9.12, p = 0.004, ES = 0.13 indicating that when
correcting for number of trials, FXS (M = 50.9, SE = 0.44)
showed higher theta power than TDC (M = 49.1, SE = 0.39).
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FIGURE 3 | (A) Single trial power (STP) for TDC, FXS, and difference maps (FXS minus TDC) for the habituation task. (B) Inter-trial coherence (ITC) for TDC, FXS,
and difference maps (FXS minus TDC) for the habituation task. Black boxes in the difference maps indicate clusters with significant group differences. Warmer colors
(reds, yellows) in the difference maps (right column) indicate higher phase-locking or higher power for FXS and cooler colors (blues, greens) indicate higher values for
TDC.
There were no gender effects on theta power. For alpha (8–
12 Hz) power, however, there was no main effect of group,
but a group by gender interaction, F(1,62) = 4.81, p = 0.03,
ES = 0.07. FXS females (M = 49.2, SE = 0.82) showed higher
alpha power than TDC females (M = 46.5, SE = 0.75) while
FXS males (M = 48.07, SE = 0.69) and TDC males did not
differ (M = 48.46, SE = 0.61). For gamma (31–70 Hz) power
across the entire trial, there was a marginal effect of group,
F(1,62) = 3.6, p = 0.06, ES = 0.05 indicating that FXS patients
(M = 33.6, SE = 0.42) had marginally higher gamma power
than TDC (M = 32.5, SE = 0.38). While there was a main
effect of gender, F(1,62) = 5.63, p = 0.02, ES = 0.08 (males have
more power than females), there was no interaction between
group and gender.
For baseline-corrected single-trial power, FXS showed
increased power in the beta/low gamma range (23–33 Hz) during
stimulus onset for the initial stimulus only, F(1,63) = 10.97,
p = 0.002, ES = 0.15. There were no effects of age, trial count, or
gender on this comparison.
Chirp
Point-by-point t-tests on time-frequency plots for ITC and STP
(corrected for multiple comparisons) revealed 4 time-frequency
clusters with significant differences between FXS and TDC
(Figure 4). There was a main effect of group for alpha band
(6–13 Hz) phase-locking (ITC) to the onset of the stimulus (92–
308 ms post-stimulus), F(1,70) = 7.12, p = 0.009, ES = 0.09
indicating that FXS (M = 0.14, SE = 0.01) showed stronger
phase-locking to the stimulus onset than did TDC (M = 0.09,
SE = 0.01), consistent with habituation findings of increased ERP
amplitude to auditory stimuli. Age was a significant covariate
F(1,70) = 5.55, p = 0.02, ES = 0.07. There was a main
effect of group for phase-locking (ITC) to the chirp stimulus
(676–1066 ms post-stimulus, while the stimulus was in the
low gamma oscillatory range) in the low gamma (31–57 Hz)
band, F(1,71) = 5.65, p = 0.02, ES = 0.07 indicating that FXS
(M = 0.11, SE = 0.01) were less able to lock in to the chirp
oscillatory stimulus than TDC (M = 0.15, SE = 0.01). There was
also a group by gender interaction, F(1,71) = 5.00, p = 0.03,
ES = 0.07 indicating that while both males and females with
FXS had lower phase-locking values, FXS females (M = 0.13,
SE = 0.02) were more similar to both TDC females (M = 0.14,
SE = 0.02) and TDC males (M = 0.16, SE = 0.02) than were
FXS males (M = 0.08, SE = 0.02). Age was not a significant
covariate (p = 0.97).
Gender effects were also found for ongoing (entire trial) theta
power (3–7 Hz) during the chirp stimulus. First, there was a main
effect of group, F(1,70) = 8.39, p = 0.005, ES = 0.11 indicating that
FXS (M = 50.68, SE = 0.43) had higher theta (3–7 Hz) power than
TDC (M = 48.93, SE = 0.40). There was also a group by gender
interaction, F(1,70) = 5.74, p = 0.02, ES = 0.08. FXS females
(M = 51.33, SE = 0.67) showed more theta power than TDC
females (M = 48.19, SE = 0.58) while FXS (M = 50.03, SE = 0.53)
and TDC (M = 49.65, SE = 0.52) males did not differ. For theta
power, trial number was a significant covariate F(1,70) = 7.1,
p = 0.01, ES = 0.09, and was retained in the analyses but age was
not (p = 0.74).
For ongoing (entire trial) gamma (31–70 Hz) power,
there was a main effect of group, F(1,71) = 7.4, p = 0.008,
ES = 0.09 indicating that FXS (M = 33.58, SE = 0.32) showed
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FIGURE 4 | (A) Single trial power (STP) for TDC, FXS, and difference maps (FXS minus TDC) for the chirp task. (B) Inter-trial coherence (ITC) for TDC, FXS, and
difference maps (FXS minus TDC) for the chirp task. Black boxes in the difference maps indicate clusters with significant group differences. Warmer colors (reds,
yellows) in the difference maps (right column) indicate higher phase-locking or higher power for FXS and cooler colors (blues, greens) indicate higher values for TDC.
Chirp stimulus schematic is represented bottom center relative to x-axis timing.
FIGURE 5 | Baseline corrected single trial power for the chirp task (A) and the habituation task (B) for TDC, FXS, and difference maps (FXS minus TDC). Black
boxes in the difference maps indicate clusters with significant group differences. Warmer colors (reds, yellows) in the difference maps (right column) indicate higher
power for FXS and cooler colors (blues, greens) indicate higher values for TDC.
more gamma power than TDC (M = 32.41, SE = 0.29).
While there was a main effect of gender on gamma power,
F(1,71) = 6.21, p = 0.02, ES = 0.08 (males have more gamma
power than females in general), there was no interaction
between gender and group. Age was not a significant
covariate (p = 0.07).
For baseline-corrected single trial power (Figure 5), FXS
showed a decrease in alpha/beta power (11–20 Hz) which
became significantly different from TDC during the time period
surrounding stimulus offset (∼2000 to 2500 ms), F(1,71) = 15.44,
p < 0.001, ES = 0.18. There were no effects of age, trial count, or
gender on this group difference.
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Gamma Power and Phase-Locking
For the chirp stimulus, increased gamma single trial power across
the entire trial was correlated with decreased gamma phase-
locking to the chirp stimulus for TDC (rho = −0.34, p = 0.04).
While the effect was in the same direction for FXS, it was not
significant (rho =−0.22, p = 0.21). Gamma and theta power were
also correlated for both groups (TDC rho = 0.34, p = 0.04; FXS
rho = 0.35, p = 0.03) for the chirp task but were marginal for
habituation. Gamma power was also correlated with beta power
(13–30 Hz) for both groups (TDC rho = 0.61, p < 0.001; FXS
rho = 0.49, p = 0.002), but while gamma power was also correlated
with alpha power in TDC (rho = 0.50, p = 0.001), it was not for
FXS (rho = 0.23, p = 0.18). Measures which were captured in
both tasks (single trial power for gamma and theta bands) showed
good correlation across tasks for both FXS and TDC. Gamma
power (TD rho = 0.71, p < 0.001, FXS rho = 0.76, p < 0.001), and
theta power (TD rho = 0.67, p < 0.001, FXS rho = 0.71, p < 0.001)
both showed strong correlation between chirp and habituation
tasks, suggesting good fidelity and test-retest reliability not just
in these measures but also in the multiple-user blinded data
processing approach utilized for this study.
Exploratory Clinical Correlations
Significant correlations of electrophysiology data with clinical
and behavioral measures in FXS participants are presented in
Tables 2–7. Correlations are presented for all FXS patients
first, then because gender and clinical/cognitive ability can be
confounded in FXS, separated by gender. Increased gamma
power and theta power were significantly related to a number
of clinical ratings, including the ABC. Vineland subscale
measures were also correlated with a number of spectral EEG
measures across habituation and chirp tasks, primarily driven by
correlations within female patients. Behavioral measures from the
KiTAP were strongly correlated with spectral EEG measures, but
most strongly correlated variables differed by gender.
DISCUSSION
The current study findings replicate and extend our previous
findings of increased auditory N1 ERP amplitude, decreased
gamma phase locking to a chirp stimulus, and increased gamma
single trial power during the chirp task. We did not strongly
replicate our prior finding of reduced habituation, although
the general patterns seen across ERP repetitions is remarkably
similar between our original study and the current. We utilized
a larger sample in this study, enabling studies of effects in
females who are underrepresented in the FXS research literature,
and explored correlations of electrophysiological abnormalities
with clinical and behavioral alterations associated with FXS. As
this replication study was conducted using a new EEG system,
different staff collecting and analyzing EEG data, these findings
indicate both clinical scalability and clinical relevance of the
electrophysiological findings.
Increased N1 ERP amplitude in FXS was replicated in this
larger new sample, and we additionally found increased P2 ERP
amplitude in FXS relative to TDC. In our previous work we found
Frontiers in Integrative Neuroscience | www.frontiersin.org 9 October 2019 | Volume 13 | Article 60
fnint-13-00060 October 5, 2019 Time: 14:39 # 10
Ethridge et al. Auditory EEG in Biomarkers FXS
TABLE 3 | Significant clinical correlations for FXS patients – males only.
EEG measure SCQ total score ABC social withdrawal WJIII Vineland DL Vineland social Vineland Comp
Habituation
N1 amplitude 0.63∗ −0.82∗∗
P2 amplitude −0.52∗





ITC stimulus onset 0.49∗
ITC 40 Hz chirp −0.44∗ 0.47∗
STP theta 0.53∗
STP gamma
Clinical variables with no significant correlations to EEG variables are not included. All correlations are Spearman’s rho. All correlations represent the FXS group only. Due
to the negative amplitude of the N1 ERP, negative correlations should be viewed as increased N1 amplitude correlating with increased scores on the clinical/behavioral
measure. Blank = N.S. ∗p < 0.05, ∗∗p < 0.01.
TABLE 4 | Significant clinical correlations for FXS patients – females only.













N1 amplitude 0.71∗ 0.75∗
P2 amplitude −0.70∗ 0.74∗ −0.84∗∗ −0.73∗ −0.73∗ −0.75∗
% habituation S1 to S4
STP theta −0.70∗
STP alpha
STP gamma −0.71∗ −0.86∗∗ −0.69∗ −0.75∗
Chirp
ITC stimulus onset
ITC 40 Hz chirp −0.77∗ −0.67∗
STP theta
STP gamma −0.80∗∗
Clinical variables with no significant correlations to EEG variables are not included. All correlations are Spearman’s rho. All correlations represent the FXS group only. Due
to the negative amplitude of the N1 ERP, negative correlations should be viewed as increased N1 amplitude correlating with increased scores on the clinical/behavioral
measure. Blank = N.S. ∗p < 0.05, ∗∗p < 0.01.
a marginal difference in N1 ERP amplitude between groups for
the response to the initial stimulus, and significant amplitude
differences for repeated stimuli, although ERP waveform plots
suggested potentially larger amplitudes to all four stimuli. Here
with more power to detect differences between groups, we show
increased N1 amplitudes to all four stimuli in the stimulus
train. We additionally found increased P2 amplitudes to all four
stimuli in FXS, suggesting a generally hyper-excitable response
throughout stimulus processing. Although we noted a possible
post hoc difference between groups for habituation measured as
percent change from the initial stimulus (S1) to the final stimulus
(S4), we did not entirely replicate previous findings of decreased
habituation of the N1 response across all repetitions, suggesting
that the decrement in ERP amplitudes with repeated stimulation
may not be a robust observation. One possibility for the lack of
replication is, in the effort to increase translation between mouse
and human, the change in stimulus from a 1000 Hz tone to a
white noise burst. Increased stimulation of auditory cortices may
have introduced the possibility of lateral inhibition effects, which
can mimic habituation by decreasing ERP amplitudes for stimuli
presented in close succession (Pantev et al., 2004). Rotschafer
and Razak (2013) show broadened frequency tuning curves for
individual neurons in auditory cortex in fmr1 KO mice, which
may make FXS particularly sensitive to lateral inhibition effects.
Alternatively, inhibitory interneuron dysfunction is characteristic
of FXS (Cea-Del Rio and Huntsman, 2014), which may decrease
lateral inhibition in FXS (Franco et al., 2017). Future work with
masking stimuli is necessary to parse these effects and provide
a mechanistic explanation for the differences in habituation
effects found here.
The significantly hyper-excitable response (increased N1
amplitude) to repeated stimuli may still result in an increased
attention to and lack of behavioral habituation to ongoing sounds
(ability to “tune out”) in the environment. Indeed, for males,
increased N1 amplitude was correlated with increased alertness
and vigilance during Woodcock Johnson Auditory Attention
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TABLE 5 | Significant behavioral correlations for FXS patients.







STP gamma −0.39∗ −0.39∗
Chirp
ITC stimulus onset 0.37∗
ITC 40 Hz chirp 0.43∗
STP theta −0.39∗
STP gamma −0.44∗ −0.38∗ −0.44∗
Clinical variables with no significant correlations to EEG variables are not included. All correlations are Spearman’s rho. All correlations represent the FXS group only. Due
to the negative amplitude of the N1 ERP, negative correlations should be viewed as increased N1 amplitude correlating with increased scores on the clinical/behavioral
measure. Blank = N.S. ∗p < 0.05, ∗∗p < 0.01.
Test. Interestingly, although FXS males and females did not
differ on N1 amplitudes, the clinical relevance for increased
N1 amplitude shows opposite effects based on gender: for
males, increased N1 amplitude was associated with decreased
scores on the SCQ, indicating fewer autism-like characteristics,
and increased scores on the Woodcock-Johnson Tests. Indeed,
individuals with idiopathic autism commonly show reduced ERP
amplitudes relative to TDC (Jeste and Nelson, 2009), and in this
case the hyper-excitable N1 response associated hyper-vigilance
may improve ability to complete cognitive tests in individuals
with intellectual disability. This is the first study known to
date that links neural hyper-excitability to cognitive functioning
in FXS. In females, however, increased N1 and P2 amplitudes
were associated with decreased scores on the Vineland Adaptive
Behavior Scales. This suggests that among females with FXS,
neural hyper-excitability, and in turn hyper-vigilance, may impair
functional abilities more broadly. However, it remains less clear
whether this a gender-effect or due to the fact that females with
FXS have more modest or no intellectual disabilities. Percent
habituation also showed unusual gender effects, in that males
with stronger habituation showed higher SCQ scores and lower
Vineland scores, while females did not show correlations between
these variables and habituation, suggesting that habituation and
N1 amplitude are dissociable effects and may differentially impact
clinical response. However, clinical correlations are presented as
exploratory analyses, and further work designed to test specific
clinical hypotheses is necessary to disentangle both gender and
ERP effects on clinical variables.
A new finding for the habituation task was increased theta
and alpha power in FXS relative to TDC. Our previous
work showed similar trends (Ethridge et al., 2016) but with
increased statistical power in the current study these group
differences were statistically significant. Increased theta power
has been commonly found for FXS in the resting EEG literature
(Sabaratnam et al., 2001; Van der Molen and Van der Molen,
2013; Wang et al., 2017) and may reflect a compensatory response
to reduced alpha-range thalamic modulation of high frequency
TABLE 6 | Significant behavioral correlations for FXS patients – males only.













ITC 40 Hz chirp 0.52∗
STP theta
STP gamma −0.45∗
Clinical variables with no significant correlations to EEG variables are not included.
All correlations are Spearman’s rho. All correlations represent the FXS group
only. Due to the negative amplitude of the N1 ERP, negative correlations should
be viewed as increased N1 amplitude correlating with increased scores on the
clinical/behavioral measure. Blank = N.S. ∗p < 0.05, ∗∗p < 0.01.
cortical oscillations (Wang et al., 2017). Both theta and alpha
oscillations may reflect thalamocortical modulation, but theta
modulation is typically associated with longer range integration
of cortical activity measured over anterior scalp and thus may be
specialized for different functions relative to alpha, which is more
commonly found to couple with gamma over posterior scalp
(Canolty and Knight, 2010). The group by gender interaction for
alpha power is interesting, in that FXS females do not show the
reduced alpha (commonly associated with thalamic modulation)
power that has previously been found in resting EEG literature
with FXS patients (Van der Molen and Van der Molen, 2013;
Wang et al., 2017); in fact, they showed increased alpha power
relative to females without FXS.
Previous EEG literature in FXS has generally been
underpowered to detect gender differences. Given that males
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TABLE 7 | Significant behavioral correlations for FXS patients – females only.










ITC 40 Hz chirp
STP theta
STP gamma
EEG measures with no significant correlations to clinical variables are not included.
All correlations are Spearman’s rho. All correlations represent the FXS group
only. Due to the negative amplitude of the N1 ERP, negative correlations should
be viewed as increased N1 amplitude correlating with increased scores on the
clinical/behavioral measure. Blank = N.S. ∗p < 0.05, ∗∗p < 0.01.
and females both showed increased theta and gamma power
and that they are correlated with each other, while alpha
and gamma power are not, this finding may indicate a more
complex relationship between high frequency (gamma) power
abnormalities in FXS and thalamocortical modulation via alpha
oscillations. This finding may be task-specific, since increased
low frequency power in FXS was largely confined to the theta
frequency band, where FXS females showed even more marked
increases, even though both males and females with FXS showed
increased gamma power. If the increased theta power does
represent a compensatory effort to reduce high frequency activity
as proposed previously, then this may indicate that female FXS
patients may in part have higher functioning because of a more
preserved ability to mobilize this response.
For the chirp task, we replicated previous findings of reduced
ability to synchronize (phase-lock) high-frequency neural activity
to the chirp stimulus. However, a group by gender interaction
suggests that FXS females are considerably less impaired on
this ability than FXS males. For both males and females,
though, decreased phase locking to the chirp stimulus was
associated with increased autism-like characteristics on the
SCQ, similar to our previous findings (Ethridge et al., 2017).
For males, cortical synchronization deficits were associated
with reduced behavioral flexibility on the KiTAP, whereas the
same deficits were associated with increased social problems in
females. Cortical synchronization deficits were also associated
with cognitive deficits on the Woodcock Johnson Auditory
Attention Tests in males. Both males and females showed
increased gamma power, although this finding was more robust
in the chirp task, which may be due to stimulus-related effects,
in that the chirp stimulus drives cortical oscillations in the
gamma frequency range while the habituation task does not.
For both tasks, increased gamma power was associated with
decreased deviation IQ scores, suggesting a significant overall
functional impairment associated with increased high-frequency
neural “noise.” Indeed, gamma power correlated with increased
distractibility on the KiTAP test and lower adaptive behavior
scores on the Vineland, the latter mostly driven by a strong
relationship between gamma power and adaptive behavior
scores in females. Gamma power was also associated with an
increase in severity of a number of behavioral problems and
psychiatric issues, including irritability, stereotyped behaviors
and speech, and hyperactivity. although these correlations were
not significant when separated by gender, suggesting that they
may correlate most strongly to differences in symptom severity
that are commonly found to be associated with gender in FXS
patients. These gender differences in clinical relevance for gamma
power may also reflect the gender differences seen above in the
theta and alpha bands, which may suggest a different effect of
low frequency modulation of gamma power between genders.
Future studies with specific clinical hypotheses will be necessary
to examine the relationship between gender, symptom severity
and EEG abnormalities.
The significant correlation between phase-locking
abnormalities and increased non-specific gamma power was only
partially replicated in this study, although the direction of the
effect was the same as previously found (Ethridge et al., 2017).
We have characterized increased gamma power as an increase
in background neural “noise,” reducing overall signal-to-noise
ratio (SNR) of sensory processing in auditory cortex. The overall
reduction in strength for this comparison for both TD and FXS
may be due to equipment differences between this study and
the previous. Saline-based EEG systems like the one employed
here typically have a higher impedance threshold and thus lower
SNR, which although sensitive enough to capture overall group
differences in gamma, may be less sensitive to capture smaller
variations in gamma between individuals. Still, both gamma
deficits were replicated in this sample, further highlighting
deficits in neural synchronization related to local network
excitation/inhibition balance supported by FXS translational
rodent models and shown here to be related to core clinical
deficits in FXS. In addition, the baseline-corrected single trial
power findings from both tasks, of enhanced processing during
the ERP at stimulus onset and then decreased or desynchronized
low frequency activity during the chirp, suggest an increase
in cortical “effort” accompanying processing the stimulus for
FXS which may persist after stimulus offset and may indicate a
potential homeostatic response to gamma processing deficits.
FXS increase their gamma power relative to baseline similarly to
TDC, however, the similar increase in gamma power riding on
top of already significantly increased baseline power produces
the group differences in un-baseline-corrected single trial
gamma power and which is particularly evident during the
chirp stimulus, which drives oscillatory networks at gamma
frequencies. Similar findings in individuals with autism and their
first degree relatives (Rojas et al., 2008; De Stefano et al., 2019)
support a possible pathophysiological link in gamma power
regulation across neurodevelopmental disorders.
Preclinical work in Fmr1 knockout mice supports a
mechanism for gamma abnormalities in decreased excitatory
drive on fast-spiking inhibitory interneurons, resulting in
increased and poorly synchronized pyramidal cell firing in
the gamma range at rest and during stimulus processing
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(Gibson et al., 2008). Recent work suggests that intrinsic
excitability in auditory cortex appears to be largely driven
by synaptic activity between layers 2/3 and layer 5, which in
contrast to previous work demonstrating network synchrony
deficits, show a hyper-synchrony (Goswami et al., 2019). This
hyper-synchronous response between cortical layers in the
gamma frequency band may underlie the increased overall
gamma power seen when neural activity is measured at the
scalp, since increased gamma oscillatory activity is necessary
to produce signals measurable at distant sources. This hyper-
synchrony is also consistent with previous findings of poor
stimulus-related synchrony, both at the slice level (Gibson et al.,
2008) and in in vivo reductions in gamma phase-locking in
both humans (seen here) and in Fmr1 KO mice (Lovelace et al.,
2018). Phase-locking is driven by a resetting of the phase of
ongoing oscillations in order to process an incoming stimulus.
Intrinsically hyper-synchronous, hyper-excitable networks may
be difficult to disrupt and modulate in order to produce accurate
phase resetting, both reducing the signal processing ability and
increasing the background “noise” of off-stimulus neural firing.
Interestingly, increased ability to phase-reset and phase-lock
gamma oscillations to the chirp stimulus was associated with
increased behavioral flexibility on the KiTAP for both males
and females with FXS, suggesting that local cortical flexibility
measured at the sensory level may be related to higher-order
cognitive flexibility.
Translational work with Fmr1 KO mice has reported similar
findings to those reported here on both the habituation (Lovelace
et al., 2016) and chirp tasks (Lovelace et al., 2018). An additional
important step is necessary to fully validate these measures
as functional outcome measure biomarkers and translate these
findings for human clinical trials: scalability. This study addresses
clinical scalability in a number of ways. First, we utilized a
new group of subjects from a new clinic that recruits from a
geographically distinct area from our previous work. Replication
of our findings in this new sample suggests that these measures
are robust to differences based on recruitment area, which is
particularly important for FXS clinical trials which commonly
utilize multi-site data collection strategies to increase patient
numbers. Second, we used a different type of EEG equipment,
in this case a saline-based EGI system, as compared to our
previous work which used gel-based electrodes. Although we
may have observed some minor system-related differences (see
discussion above on signal to noise ratio), findings appear to
be largely robust to system differences as well as reduced SNR
associated with the EGI nets. This finding is important as
saline-based EEG systems are becoming increasingly popular
due to their ease of use, comfort, speed at which they can
be applied, and reduced mess, all of which are important to
reducing both patient and clinician burden as well as increasing
the possibility of collecting useable data from more behaviorally
impaired individuals. Equipment-invariance is also important
due to the significant variation in existing equipment across
clinics; purchasing identical EEG systems may not be financially
feasible for large multi-site studies. Third, we used a white noise
carrier sound for both habituation and chirp stimuli, which
differs from the 1000 Hz carrier tone used in our previous
studies. The white noise carrier sound stimulates a larger area
of auditory cortex and produces a more robust neural response.
Because it uses a wide range of frequencies rather than just one,
the white noise sound can also be directly translated to rodent
models without modification for hearing thresholds. The white
noise sound is also less harsh-sounding to participants, and may
allow for data collection in individuals with higher levels of
sensory sensitivity. Our findings appear to be robust to these
practical improvements in the stimulus properties, although see
the discussion above regarding the habituation findings and white
noise stimuli. Finally, we collected and analyzed the current
dataset using a laboratory-based approach, with multiple research
assistants and multiple data analysts all contributing to data
collection, preprocessing, and screening. While all researchers
involved were highly trained for reliability on their respective
duties, this approach stills differs considerably from our previous
work, which was collected and analyzed by a single individual.
The laboratory approach is more consistent with large-scale
studies with multiple research teams, and indicates that our
findings are robust to the increase in error variance intrinsic to
procedures with more decision-makers and decision points. We
also analyzed the data slightly differently in order to produce
a priori data cut-offs that can be utilized for individual data
evaluation as well as interim data analyses, rather than data-
driven approaches that can only be used once the entire dataset is
collected. We used pre-defined sensors rather than data-driven
topographic weights based on principle components analysis.
Using predefined sensors also introduces the possibility of scaling
the number of sensors necessary for data collection, reducing
clinical burden. Taken together with similar findings in related
disorders such as autism (Orekhova et al., 2008; Van Diessen
et al., 2014; De Stefano et al., 2019), the replication of our
previous work using different subjects, equipment, stimuli, and
laboratory-based techniques point to ERP amplitude and gamma
phase-locking and power as robust, clinically scalable measures
that might be useful to predict or monitor drug response in large-
scale multi-site clinical trials. Strong correlations between similar
measures (gamma and theta power) between tasks also suggests
test-retest reliability both of the measures and the laboratory-
based data analysis strategies, another important factor in clinical
trial readiness. While retest reliability for ongoing gamma
(McFadden et al., 2014) and theta (Tan et al., 2015) power
has been previously established, these findings support retest
reliability of these measures specifically for FXS, a population
for which increased response variability is sometimes a concern
(The additional preclinical work showing replication of deficits
and responsiveness to pharmaceutical intervention in FXS mouse
models (Sinclair et al., 2017; Lovelace et al., 2018) suggests these
measures may provide useful candidate biomarkers for treatment
response in FXS. Specifically, both gamma phase-locking and
power deficits show great promise as biologically grounded and
functionally robust outcome measures in future clinical trials
for FXS. Given the potential link to underlying pathophysiology,
these biomarkers may also be relevant for other disorders with
overlapping biological pathways and/or behavioral deficits that
may ultimately arise from sensory processing abnormalities.
Despite these advances, some additional questions remain.
Comparative work is still necessary to assess the specificity
of our findings to FXS relative to other neurodevelopmental
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disabilities. Second, although we did not find differences between
medicated and non-medicated patients, our sample is still not
large enough to address the effects of individual medications;
additionally, in correlational studies medication status may
be confounded with symptom severity, necessitating targeted
studies with pre-post designs. Excluding medicated patients can
exclude a majority of FXS patients, particularly males and those
with more severe clinical presentation, significantly impacting
the representativeness of our data were they to be excluded
from studies. So, we chose to retain patients in this study taking
psychiatric medications commonly used to treat FXS patients
that are not known to have significant impact on EEG measures
obtained in the present study. Further, gamma abnormalities may
be due to group differences in residual movement artifact due
to common reduced behavioral compliance in FXS, however,
preclinical studies of this question have found enhanced gamma
power in fmr1 KO mice even during movement-free periods
(Lovelace et al., 2018).
Preclinical models have provided a wealth of information
relevant to understanding the genetic alteration resulting in FXS
and its impacts on biochemical and local circuit function, but
thus far the ability to translate these results into successful human
clinical trials has been lacking. One reason for this disconnect
may be the lack of translational biomarkers robust to both
species differences and practical differences that may hinder
reproducibility. The current study provides additional support
for EEG-related neurophysiological measures as biomarkers
by replicating previous findings in human data and linking
them to a wider array of clinical features. Work is needed to
link the EEG findings to molecular and network mechanisms
in preclinical work, and also continue establishing their
translational robustness.
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